Xtant Medical Holdings

XTNT · NYSE American

$0.303+$0.012 (+4.12%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $0.291

XTNT analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $1.05 (+247.8% upside)

Low: $0.606
Now: $0.303
High: $1.58

Upgrades and downgrades

The latest rating actions, newest first

XTNT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
LUCID CAPITAL MARKETS	Sep 2, 2026	Initiates	Buy	$1.00	25%
BTIG	May 13, 2026	Maintains	Buy	$1.00	48%
BTIG	Mar 31, 2026	Maintains	Buy	$1.50 → $1.00	48%
BTIG	Nov 11, 2025	Maintains	Buy	$2.00 → $1.50	48%

The case for and against

Updated Sep 18, 2026

Bull case

Xtant Medical Holdings is poised for success in the medical technology industry as it focuses on its core business of orthobiologics and spinal implants. With the recent Dilon Technologies agreement, a strong capital position, and a discounted valuation compared to its peers, Xtant Medical is positioned for revenue growth and profitability. The company's product pipeline, including the recent launch of Trivium Shaped, showcases its commitment to innovation and meeting the needs of orthopedic and neurological surgeons. Risks include competition, legacy performance, and the need for additional capital, but the company's recent changes and clean-up process demonstrate its ability to adapt and improve. Overall, Xtant Medical has a positive outlook for future growth and potential to provide value for investors.

Bear case

Xtant Medical Holdings is facing a potential growth plateau in the near-term due to their reliance on a single distributor for a significant portion of their revenue. Ongoing inventory dynamics in the wound care market may also hinder their ability to drive sales in this segment. Additionally, their limited financial resources may impede their ability to effectively compete with larger, more established competitors in the market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.